Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Opitz L, Lehmann S, Reichl U, Wolff MW. Sulfated membrane adsorbers for economic pseudo-affinity capture of influenza virus particles. Biotechnol Bioeng 2009;103:1144-54. [PMID: 19449393 DOI: 10.1002/bit.22345] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]

For:	Opitz L, Lehmann S, Reichl U, Wolff MW. Sulfated membrane adsorbers for economic pseudo-affinity capture of influenza virus particles. Biotechnol Bioeng 2009;103:1144-54. [PMID: 19449393 DOI: 10.1002/bit.22345] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]

Number

Cited by Other Article(s)

Liu S, Li J, Cheng Q, Duan K, Wang Z, Yan S, Tian S, Wang H, Wu S, Lei X, Yang Y, Ma N. A Single-Step Method for Harvesting Influenza Viral Particles from MDCK Cell Culture Supernatant with High Yield and Effective Impurity Removal. Viruses 2024;16:768. [PMID: 38793649 PMCID: PMC11125750 DOI: 10.3390/v16050768] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2024] [Revised: 05/08/2024] [Accepted: 05/11/2024] [Indexed: 05/26/2024] Open

Abstract

Influenza vaccines, which are recommended by the World Health Organization (WHO), are the most effective preventive measure against influenza virus infection. Madin-Darby canine kidney (MDCK) cell culture is an emerging technology used to produce influenza vaccines. One challenge when purifying influenza vaccines using this cell culture system is to efficiently remove impurities, especially host cell double-stranded DNA (dsDNA) and host cell proteins (HCPs), for safety assurance. In this study, we optimized ion-exchange chromatography methods to harvest influenza viruses from an MDCK cell culture broth, the first step in influenza vaccine purification. Bind/elute was chosen as the mode of operation for simplicity. The anion-exchange Q chromatography method was able to efficiently remove dsDNA and HCPs, but the recovery rate for influenza viruses was low. However, the cation-exchange SP process was able to simultaneously achieve high dsDNA and HCP removal and high influenza virus recovery. For the SP process to work, the clarified cell culture broth needed to be diluted to reduce its ionic strength, and the optimal dilution rate was determined to be 1:2 with purified water. The SP process yielded a virus recovery rate exceeding 90%, as measured using a hemagglutination units (HAUs) assay, with removal efficiencies over 97% for HCPs and over 99% for dsDNA. Furthermore, the general applicability of the SP chromatography method was demonstrated with seven strains of influenza viruses recommended for seasonal influenza vaccine production, including H1N1, H3N2, B (Victoria), and B (Yamagata) strains, indicating that the SP process could be utilized as a platform process. The SP process developed in this study showed four advantages: (1) simple operation, (2) a high recovery rate for influenza viruses, (3) a high removal rate for major impurities, and (4) general applicability.

Collapse

Affiliation(s)

Sixu Liu Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.)
Jingqi Li Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.) GenScript (Shanghai) Biotech Co., Ltd., Shanghai 200131, China
Qingtian Cheng Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.)
Kangyi Duan Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.)
Zhan Wang School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China;
Shuang Yan Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.)
Shuaishuai Tian Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.)
Hairui Wang Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.) Qilu Pharmaceutical Co., Ltd., Jinan 250104, China
Shaobin Wu Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.) Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd., Beijing 100176, China
Xinkui Lei Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.) Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd., Beijing 100176, China
Yu Yang School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, China;
Ningning Ma Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China; (S.L.); (J.L.); (Q.C.); (K.D.); (S.Y.); (S.T.); (H.W.); (S.W.); (X.L.)

Collapse

Li F, Liu B, Xiong Y, Zhang Z, Zhang Q, Qiu R, Peng F, Nian X, Wu D, Li X, Liu J, Li Z, Tu H, Wu W, Wang Y, Zhang J, Yang X. Enhanced Downstream Processing for a Cell-Based Avian Influenza (H5N1) Vaccine. Vaccines (Basel) 2024;12:138. [PMID: 38400122 PMCID: PMC10891636 DOI: 10.3390/vaccines12020138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2023] [Revised: 01/17/2024] [Accepted: 01/25/2024] [Indexed: 02/25/2024] Open

Affiliation(s)

Fang Li National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.) Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
Bo Liu National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.) Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
Yu Xiong National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.) Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
Zhegang Zhang National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.) Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
Qingmei Zhang National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.) Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
Ran Qiu National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.) Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
Feixia Peng National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.) Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
Xuanxuan Nian National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.) Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
Dongping Wu National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.) Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
Xuedan Li National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.) Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
Jing Liu National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.) Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
Ze Li National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.) Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
Hao Tu National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.) Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
Wenyi Wu National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.) Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
Yu Wang National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.) Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
Jiayou Zhang National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.) Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China
Xiaoming Yang National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China; (F.L.); (B.L.); (Y.X.); (Z.Z.); (Q.Z.); (R.Q.); (F.P.); (X.N.); (D.W.); (X.L.); (J.L.); (Z.L.); (H.T.); (W.W.); (Y.W.) Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China China National Biotec Group Company Limited, Beijing 100029, China

Collapse

Lothert K, Wolff MW. Affinity and Pseudo-Affinity Membrane Chromatography for Viral Vector and Vaccine Purifications: A Review. MEMBRANES 2023;13:770. [PMID: 37755191 PMCID: PMC10537005 DOI: 10.3390/membranes13090770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/21/2023] [Revised: 08/11/2023] [Accepted: 08/29/2023] [Indexed: 09/28/2023]

Hillebrandt N, Hubbuch J. Size-selective downstream processing of virus particles and non-enveloped virus-like particles. Front Bioeng Biotechnol 2023;11:1192050. [PMID: 37304136 PMCID: PMC10248422 DOI: 10.3389/fbioe.2023.1192050] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Accepted: 05/08/2023] [Indexed: 06/13/2023] Open

Fabrication and Characterization of a Cellulose Monolith-like Particle for Virus Purification. Biochem Eng J 2023. [DOI: 10.1016/j.bej.2023.108849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]

Gautam S, Xin D, Garcia AP, Spiesschaert B. Single-step rapid chromatographic purification and characterization of clinical stage oncolytic VSV-GP. Front Bioeng Biotechnol 2022;10:992069. [PMID: 36394051 PMCID: PMC9649487 DOI: 10.3389/fbioe.2022.992069] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2022] [Accepted: 10/13/2022] [Indexed: 09/14/2023] Open

Continuous purification of influenza A virus particles using pseudo-affinity membrane chromatography. J Biotechnol 2021;342:139-148. [PMID: 34678401 DOI: 10.1016/j.jbiotec.2021.10.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2020] [Revised: 08/26/2021] [Accepted: 10/11/2021] [Indexed: 11/22/2022]

Fei C, Gao J, Fei C, Ma L, Zhu W, He L, Wu Y, Song S, Li W, Zhou J, Liao G. A flow-through chromatography purification process for Vero cell-derived influenza virus (H7N9). J Virol Methods 2021;301:114408. [PMID: 34896455 DOI: 10.1016/j.jviromet.2021.114408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Revised: 10/29/2021] [Accepted: 12/07/2021] [Indexed: 11/29/2022]

Bissinger T, Wu Y, Marichal-Gallardo P, Riedel D, Liu X, Genzel Y, Tan WS, Reichl U. Towards integrated production of an influenza A vaccine candidate with MDCK suspension cells. Biotechnol Bioeng 2021;118:3996-4013. [PMID: 34219217 DOI: 10.1002/bit.27876] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2021] [Revised: 06/01/2021] [Accepted: 06/23/2021] [Indexed: 12/11/2022]

Abstract

Seasonal influenza epidemics occur both in northern and southern hemispheres every year. Despite the differences in influenza virus surface antigens and virulence of seasonal subtypes, manufacturers are well-adapted to respond to this periodical vaccine demand. Due to decades of influenza virus research, the development of new influenza vaccines is relatively straight forward. In similarity with the ongoing coronavirus disease 2019 pandemic, vaccine manufacturing is a major bottleneck for a rapid supply of the billions of doses required worldwide. In particular, egg-based vaccine production would be difficult to schedule and shortages of other egg-based vaccines with high demands also have to be anticipated. Cell culture-based production systems enable the manufacturing of large amounts of vaccines within a short time frame and expand significantly our options to respond to pandemics and emerging viral diseases. In this study, we present an integrated process for the production of inactivated influenza A virus vaccines based on a Madin-Darby Canine Kidney (MDCK) suspension cell line cultivated in a chemically defined medium. Very high titers of 3.6 log₁₀ (HAU/100 µl) were achieved using fast-growing MDCK cells at concentrations up to 9.5 × 10⁶ cells/ml infected with influenza A/PR/8/34 H1N1 virus in 1 L stirred tank bioreactors. A combination of membrane-based steric-exclusion chromatography followed by pseudo-affinity chromatography with a sulfated cellulose membrane adsorber enabled full recovery for the virus capture step and up to 80% recovery for the virus polishing step. Purified virus particles showed a homogenous size distribution with a mean diameter of 80 nm. Based on a monovalent dose of 15 µg hemagglutinin (single-radial immunodiffusion assay), the level of total protein and host cell DNA was 58 µg and 10 ng, respectively. Furthermore, all process steps can be fully scaled up to industrial quantities for commercial manufacturing of either seasonal or pandemic influenza virus vaccines. Fast production of up to 300 vaccine doses per liter within 4-5 days makes this process competitive not only to other cell-based processes but to egg-based processes as well.

Collapse

B Carvalho S, Peixoto C, T Carrondo MJ, S Silva RJ. Downstream processing for influenza vaccines and candidates: An update. Biotechnol Bioeng 2021;118:2845-2869. [PMID: 33913510 DOI: 10.1002/bit.27803] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Revised: 04/10/2021] [Accepted: 04/16/2021] [Indexed: 02/07/2023]

Hein MD, Arora P, Marichal-Gallardo P, Winkler M, Genzel Y, Pöhlmann S, Schughart K, Kupke SY, Reichl U. Cell culture-based production and in vivo characterization of purely clonal defective interfering influenza virus particles. BMC Biol 2021;19:91. [PMID: 33941189 PMCID: PMC8091782 DOI: 10.1186/s12915-021-01020-5] [Citation(s) in RCA: 16] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Accepted: 04/01/2021] [Indexed: 01/15/2023] Open

Abstract

BACKGROUND

Infections with influenza A virus (IAV) cause high morbidity and mortality in humans. Additional to vaccination, antiviral drugs are a treatment option. Besides FDA-approved drugs such as oseltamivir or zanamivir, virus-derived defective interfering (DI) particles (DIPs) are considered promising new agents. IAV DIPs typically contain a large internal deletion in one of their eight genomic viral RNA (vRNA) segments. Consequently, DIPs miss the genetic information necessary for replication and can usually only propagate by co-infection with infectious standard virus (STV), compensating for their defect. In such a co-infection scenario, DIPs interfere with and suppress STV replication, which constitutes their antiviral potential.

RESULTS

In the present study, we generated a genetically engineered MDCK suspension cell line for production of a purely clonal DIP preparation that has a large deletion in its segment 1 (DI244) and is not contaminated with infectious STV as egg-derived material. First, the impact of the multiplicity of DIP (MODIP) per cell on DI244 yield was investigated in batch cultivations in shake flasks. Here, the highest interfering efficacy was observed for material produced at a MODIP of 1E-2 using an in vitro interference assay. Results of RT-PCR suggested that DI244 material produced was hardly contaminated with other defective particles. Next, the process was successfully transferred to a stirred tank bioreactor (500 mL working volume) with a yield of 6.0E+8 PFU/mL determined in genetically modified adherent MDCK cells. The produced material was purified and concentrated about 40-fold by membrane-based steric exclusion chromatography (SXC). The DI244 yield was 92.3% with a host cell DNA clearance of 97.1% (99.95% with nuclease digestion prior to SXC) and a total protein reduction of 97.2%. Finally, the DIP material was tested in animal experiments in D2(B6).A2G-Mx1^r/r mice. Mice infected with a lethal dose of IAV and treated with DIP material showed a reduced body weight loss and all animals survived.

CONCLUSION

In summary, experiments not only demonstrated that purely clonal influenza virus DIP preparations can be obtained with high titers from animal cell cultures but confirmed the potential of cell culture-derived DIPs as an antiviral agent.

Collapse

Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine. Sci Rep 2020;10:16261. [PMID: 33004836 PMCID: PMC7530675 DOI: 10.1038/s41598-020-72328-5] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Accepted: 08/26/2020] [Indexed: 02/07/2023] Open

Lothert K, Dekevic G, Loewe D, Salzig D, Czermak P, Wolff MW. Upstream and Downstream Processes for Viral Nanoplexes as Vaccines. Methods Mol Biol 2020;2183:217-248. [PMID: 32959247 DOI: 10.1007/978-1-0716-0795-4_12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]

Lothert K, Pagallies F, Feger T, Amann R, Wolff MW. Selection of chromatographic methods for the purification of cell culture-derived Orf virus for its application as a vaccine or viral vector. J Biotechnol 2020;323:62-72. [PMID: 32763261 PMCID: PMC7403136 DOI: 10.1016/j.jbiotec.2020.07.023] [Citation(s) in RCA: 19] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Revised: 07/23/2020] [Accepted: 07/31/2020] [Indexed: 12/02/2022]

Abstract

•

Estimation of the isoelectric point and size of Vero cell-derived Orf virus.

•

Limited dynamic binding capacity of tested Orf virus to sulfated cellulose.

•

Purification of Orf virus by steric exclusion chromatography lead to 84 % recovery.

•

Hydrophobic interaction chromatography suitable for Orf virus purification.

•

Promising unit operations for a scalable DSP to produce Orf virus viral vectors.

In recent years, the Orf virus has become a promising tool for protective recombinant vaccines and oncolytic therapy. However, suitable methods for an Orf virus production, including up- and downstream, are very limited. The presented study focuses on downstream processing, describing the evaluation of different chromatographic unit operations. In this context, ion exchange-, pseudo-affinity- and steric exclusion chromatography were employed for the purification of the cell culture-derived Orf virus, aiming at a maximum in virus recovery and contaminant depletion. The most promising chromatographic methods for capturing the virus particles were the steric exclusion- or salt-tolerant anion exchange membrane chromatography, recovering 84 % and 86 % of the infectious virus. Combining the steric exclusion chromatography with a subsequent Capto™ Core 700 resin or hydrophobic interaction membrane chromatography as a secondary chromatographic step, overall virus recoveries of up to 76 % were achieved. Furthermore, a complete cellular protein removal and a host cell DNA depletion of up to 82 % was possible for the steric exclusion membranes and the Capto™ Core 700 combination.

The study reveals a range of possible unit operations suited for the chromatographic purification of the cell culture-derived Orf virus, depending on the intended application, i.e. a human or veterinary use, and the required purity.

Collapse

Junter GA, Lebrun L. Polysaccharide-based chromatographic adsorbents for virus purification and viral clearance. J Pharm Anal 2020;10:291-312. [PMID: 32292625 PMCID: PMC7104128 DOI: 10.1016/j.jpha.2020.01.002] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2019] [Revised: 01/10/2020] [Accepted: 01/11/2020] [Indexed: 12/20/2022] Open

Moleirinho MG, Silva RJS, Alves PM, Carrondo MJT, Peixoto C. Current challenges in biotherapeutic particles manufacturing. Expert Opin Biol Ther 2019;20:451-465. [PMID: 31773998 DOI: 10.1080/14712598.2020.1693541] [Citation(s) in RCA: 67] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]

Use of sulfated cellulose membrane adsorbers for chromatographic purification of cell cultured-derived influenza A and B viruses. Sep Purif Technol 2019. [DOI: 10.1016/j.seppur.2019.05.101] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]

Hydrophobic-interaction chromatography for purification of influenza A and B virus. J Chromatogr B Analyt Technol Biomed Life Sci 2019;1117:103-117. [DOI: 10.1016/j.jchromb.2019.03.037] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2019] [Revised: 03/28/2019] [Accepted: 03/29/2019] [Indexed: 11/17/2022]

B Carvalho S, Fortuna AR, Wolff MW, Peixoto C, M Alves P, Reichl U, JT Carrondo M. Purification of influenza virus-like particles using sulfated cellulose membrane adsorbers. JOURNAL OF CHEMICAL TECHNOLOGY AND BIOTECHNOLOGY (OXFORD, OXFORDSHIRE : 1986) 2018;93:1988-1996. [PMID: 30008506 PMCID: PMC6033026 DOI: 10.1002/jctb.5474] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 06/30/2017] [Revised: 09/30/2017] [Accepted: 10/01/2017] [Indexed: 06/08/2023]

Purification of cell culture-derived influenza A virus via continuous anion exchange chromatography on monoliths. Vaccine 2018;36:3153-3160. [DOI: 10.1016/j.vaccine.2017.06.086] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2016] [Revised: 06/18/2017] [Accepted: 06/29/2017] [Indexed: 02/04/2023]

Fortuna AR, Taft F, Villain L, Wolff MW, Reichl U. Optimization of cell culture-derived influenza A virus particles purification using sulfated cellulose membrane adsorbers. Eng Life Sci 2017;18:29-39. [PMID: 32624858 DOI: 10.1002/elsc.201700108] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2017] [Revised: 08/31/2017] [Accepted: 09/05/2017] [Indexed: 11/08/2022] Open

Ribeiro DA, Passos DF, Ferraz HC, Castilho LR. Intermediate purification of CHO-derived recombinant human Factor IX using hydrophobic interaction membrane-based chromatography and its comparison to a sulfated resin. Electrophoresis 2017;38:2900-2908. [DOI: 10.1002/elps.201700226] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2017] [Revised: 08/26/2017] [Accepted: 08/27/2017] [Indexed: 11/07/2022]

A fast and efficient purification platform for cell-based influenza viruses by flow-through chromatography. Vaccine 2017;36:3146-3152. [PMID: 28342667 DOI: 10.1016/j.vaccine.2017.03.016] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2016] [Revised: 03/03/2017] [Accepted: 03/08/2017] [Indexed: 01/01/2023]

Marichal-Gallardo P, Pieler MM, Wolff MW, Reichl U. Steric exclusion chromatography for purification of cell culture-derived influenza A virus using regenerated cellulose membranes and polyethylene glycol. J Chromatogr A 2016;1483:110-119. [PMID: 28069171 DOI: 10.1016/j.chroma.2016.12.076] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2016] [Revised: 12/12/2016] [Accepted: 12/27/2016] [Indexed: 01/08/2023]

Wang W, Voigt A, Sundmacher K. The interaction of protein-coated bionanoparticles and surface receptors reevaluated: how important is the number of bonds? SOFT MATTER 2016;12:6451-6462. [PMID: 27411954 DOI: 10.1039/c6sm00995f] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]

Weigel T, Solomaier T, Wehmeyer S, Peuker A, Wolff MW, Reichl U. A membrane-based purification process for cell culture-derived influenza A virus. J Biotechnol 2015;220:12-20. [PMID: 26712479 DOI: 10.1016/j.jbiotec.2015.12.022] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/30/2015] [Revised: 12/13/2015] [Accepted: 12/15/2015] [Indexed: 11/24/2022]

Serve A, Pieler MM, Benndorf D, Rapp E, Wolff MW, Reichl U. Comparison of Influenza Virus Particle Purification Using Magnetic Sulfated Cellulose Particles with an Established Centrifugation Method for Analytics. Anal Chem 2015;87:10708-11. [DOI: 10.1021/acs.analchem.5b02681] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]

A flow-through chromatography process for influenza A and B virus purification. J Virol Methods 2014;207:45-53. [DOI: 10.1016/j.jviromet.2014.06.019] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2014] [Revised: 06/20/2014] [Accepted: 06/24/2014] [Indexed: 12/22/2022]

Banjac M, Roethl E, Gelhart F, Kramberger P, Jarc BL, Jarc M, Štrancar A, Muster T, Peterka M. Purification of Vero cell derived live replication deficient influenza A and B virus by ion exchange monolith chromatography. Vaccine 2014;32:2487-92. [DOI: 10.1016/j.vaccine.2014.02.086] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2013] [Revised: 02/06/2014] [Accepted: 02/25/2014] [Indexed: 12/31/2022]

Kröber T, Wolff M, Hundt B, Seidel-Morgenstern A, Reichl U. Continuous purification of influenza virus using simulated moving bed chromatography. J Chromatogr A 2013;1307:99-110. [DOI: 10.1016/j.chroma.2013.07.081] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2012] [Revised: 07/18/2013] [Accepted: 07/22/2013] [Indexed: 11/16/2022]

Orr V, Zhong L, Moo-Young M, Chou CP. Recent advances in bioprocessing application of membrane chromatography. Biotechnol Adv 2013;31:450-65. [DOI: 10.1016/j.biotechadv.2013.01.007] [Citation(s) in RCA: 150] [Impact Index Per Article: 13.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2012] [Accepted: 01/20/2013] [Indexed: 01/03/2023]

Wolf MW, Reichl U. Downstream processing of cell culture-derived virus particles. Expert Rev Vaccines 2011;10:1451-75. [PMID: 21988309 PMCID: PMC7103681 DOI: 10.1586/erv.11.111] [Citation(s) in RCA: 93] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]

He C, Yang Z, Tong K. Downstream processing of Vero cell-derived human influenza A virus (H1N1) grown in serum-free medium. J Chromatogr A 2011;1218:5279-85. [DOI: 10.1016/j.chroma.2011.06.043] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2010] [Revised: 02/21/2011] [Accepted: 06/09/2011] [Indexed: 11/28/2022]

Iyer G, Ramaswamy S, Asher D, Mehta U, Leahy A, Chung F, Cheng KS. Reduced surface area chromatography for flow-through purification of viruses and virus like particles. J Chromatogr A 2011;1218:3973-81. [DOI: 10.1016/j.chroma.2011.04.086] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2011] [Revised: 04/26/2011] [Accepted: 04/28/2011] [Indexed: 11/26/2022]

Ohtaki N, Takahashi H, Kaneko K, Gomi Y, Ishikawa T, Higashi Y, Todokoro M, Kurata T, Sata T, Kojima A. Purification and concentration of non-infectious West Nile virus-like particles and infectious virions using a pseudo-affinity Cellufine Sulfate column. J Virol Methods 2011;174:131-5. [DOI: 10.1016/j.jviromet.2011.03.021] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2010] [Revised: 02/09/2011] [Accepted: 03/17/2011] [Indexed: 11/15/2022]

Muschin T, Han S, Kanamoto T, Nakashima H, Yoshida T. Synthesis and specific influenza A virus-adsorptive functionality of alkyl curdlan sulfate-coated membrane filter. ACTA ACUST UNITED AC 2011. [DOI: 10.1002/pola.24738] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]

Pulko I, Smrekar V, Podgornik A, Krajnc P. Emulsion templated open porous membranes for protein purification. J Chromatogr A 2011;1218:2396-401. [DOI: 10.1016/j.chroma.2010.11.069] [Citation(s) in RCA: 58] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2010] [Revised: 11/25/2010] [Accepted: 11/29/2010] [Indexed: 11/25/2022]

Ma H, Burger C, Hsiao BS, Chu B. Ultrafine Polysaccharide Nanofibrous Membranes for Water Purification. Biomacromolecules 2011;12:970-6. [DOI: 10.1021/bm1013316] [Citation(s) in RCA: 188] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]

Wolff MW, Siewert C, Hansen SP, Faber R, Reichl U. Purification of cell culture-derived modified vaccinia ankara virus by pseudo-affinity membrane adsorbers and hydrophobic interaction chromatography. Biotechnol Bioeng 2010;107:312-20. [PMID: 20506129 DOI: 10.1002/bit.22797] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]

Wolff MW, Siewert C, Lehmann S, Hansen SP, Djurup R, Faber R, Reichl U. Capturing of cell culture-derived modified Vaccinia Ankara virus by ion exchange and pseudo-affinity membrane adsorbers. Biotechnol Bioeng 2010;105:761-9. [PMID: 19891005 DOI: 10.1002/bit.22595] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]

Abstract

Smallpox is an acute, highly infectious viral disease unique to humans, and responsible for an estimated 300-500 million deaths in the 20th century. Following successful vaccination campaigns through the 19th and 20th centuries, smallpox was declared eradicated by the World Health Organization in 1980. However, the threat of using smallpox as a biological weapon prompted efforts of some governments to produce smallpox vaccines for emergency preparedness. An additional aspect for the interest in smallpox virus is its potential use as a platform technology for vector vaccines. In particular, the latter requires a high safety level for routine applications. IMVAMUNE, a third generation smallpox vaccine based on the attenuated Modified Vaccinia Ankara (MVA) virus, demonstrates superior safety compared to earlier generations and represents therefore an interesting choice as viral vector. Current downstream production processes of Vaccinia virus and MVA are mainly based on labor-intensive centrifugation and filtration methods, requiring expensive nuclease treatment in order to achieve sufficient low host-cell DNA levels for human vaccines. This study compares different ion exchange and pseudo-affinity membrane adsorbers (MA) to capture chicken embryo fibroblast cell-derived MVA-BN after cell homogenization and clarification. In parallel, the overall performance of classical bead-based resin chromatography (Cellufine sulfate and Toyopearl AF-Heparin) was investigated. The two tested pseudo-affinity MA (i.e., sulfated cellulose and heparin) were superior over the applied ion exchange MA in terms of virus yield and contaminant depletion. Furthermore, studies confirmed an expected increase in productivity resulting from the increased volume throughput of MA compared to classical bead-based column chromatography methods. Overall virus recovery was approximately 60% for both pseudo-affinity MA and the Cellufine sulfate resin. Depletion of total protein ranged between 86% and 102% for all tested matrices. Remaining dsDNA in the product fraction varied between 24% and 7% for the pseudo-affinity chromatography materials. Cellufine sulfate and the reinforced sulfated cellulose MA achieved the lowest dsDNA product contamination. Finally, by a combination of pseudo-affinity with anion exchange MA a further reduction of host-cell DNA was achieved.

Collapse

Opitz L, Hohlweg J, Reichl U, Wolff MW. Purification of cell culture-derived influenza virus A/Puerto Rico/8/34 by membrane-based immobilized metal affinity chromatography. J Virol Methods 2009;161:312-6. [PMID: 19591872 DOI: 10.1016/j.jviromet.2009.06.025] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2009] [Revised: 06/22/2009] [Accepted: 06/29/2009] [Indexed: 11/18/2022]